Thromboembolic complications in β-thalassemia: Beyond the horizon

Thrombosis Research

Volumn 120, Issue 6, 2007, Pages 783-789

  Panigrahi, Inusha ^a   Agarwal, Sarita ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

thalassemia; Cerebellar infarct; Cerebro vascular disease; CVA; Hemoglobinopathy; Platelets; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING INHIBITOR; CLOPIDOGREL; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; WARFARIN;

ARTERY THROMBOSIS; BETA THALASSEMIA; BLOOD CLOTTING; HEART DISEASE; HORMONE DEFICIENCY; HUMAN; HYPERCOAGULABILITY; LIVER DYSFUNCTION; LOW DRUG DOSE; MORBIDITY; PRIORITY JOURNAL; SHORT SURVEY; THALASSEMIA MAJOR; THROMBOEMBOLISM;

ADULT; BETA-THALASSEMIA; BLOOD PLATELETS; ERYTHROCYTE MEMBRANE; HUMANS; INCIDENCE; MALE; THROMBOEMBOLISM;

EID: 34548747383     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.01.015     Document Type: Short Survey

References (49)

1. Cappellini M.D., Grespi E., Cassinerio E., Bignamini D., and Fiorelli G. Coagulation and splenectomy: an overview. Ann N Y Acad Sci 1054 (2005) 317-324
2. Mohamed N., and Jackson N. Severe thalassaemia intermedia: clinical problems in the absence of hypertransfusion. Blood Rev 12 (1998) 163-170
3. Moratelli S., De Sanctis V., Gemmati D., Serino M.L., Mari R., Gamberini M.R., et al. Thrombotic risk in thalassemic patients. J Pediatric Endocrinol Metab 11 Suppl 3 (1998) 915-921
4. Eldor A., and Rachmilewitz E.A. The hypercoagulable state in thalassemia. Blood 99 (2002) 36-43
5. Borgna-Pignatti C., Rugolotto S., De Stefano P., Zhao H., Cappellini M.D., Del Vecchio G.C., et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89 (2004) 1187-1193
6. Zurlo M.G., De Stefano P., Borgna Pignatti C., Di Palma A., Piga A., Melevendi C., et al. Survival and cause of death in thalassemia major. Lancet I (1989) 27-30
7. Naithani R., Chandra J., Narayan S., Sharma S., and Singh V. Thalassemia major-on the verge of bleeding or thrombosis?. Hematology 11 (2006) 57-61
8. Sok J., Su W., and Hopkins M.A. Portal vein thrombosis following laparoscopic splenectomy for beta-thalassemia: a case study. Surg Endosc 15 (2001) 1489
9. Fujita F., Lyass S., Otsuka K., Giordano L., Rosenbaum D.I., Khalili T.M., et al. Portal vein thrombosis following splenectomy: identification of risk factors. Am Surg 69 (2003) 951-956
10. Finkelstein Y., Yaniv I., Berant M., Zilber R., Garty B.Z., Epstein O., et al. Central venous line thrombosis in children and young adults with thalassemia major. Pediatr Hematol Oncol 21 (2004) 375-381
11. Sebire G., Tabarki B., Saunders D.E., Leroy I., Liesner R., Saint-Martin C., et al. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain 128 (2005) 477-489
12. Ciceri L., Amato M., Cappellini M.D., and Fiorelli G. A case of pulmonary thromboembolism in thalassemia intermedia: are these patients at risk for thrombotic events?. Ann Ital Med Interna 15 (2000) 218-820
13. Taher A., Abou-Mourad Y., Abchee A., Zalouaa P., and Samseddin A. Pulmonary thromboembolism in beta-thalassemia intermedia; are we aware of this complication?. Hemoglobin 26 (2002) 107-1012
14. Singer S.T., Kuypers F.A., Styles L., Vichinsky E.P., Foote D., and Rosenfield H. Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol 81 (2006) 670-675
15. Sumiyoshi A., Thakerngpol K., and Sonakul D. Pulmonary microthromboemboli in thalassemic cases. Southeast J Trop Med Public Health 23 Suppl 2 (1992) 29-31
16. Grisaru D., Rachmilewitz E.A., Mosseri M., Gotsman M., Lafair J.S., Okon E., et al. Cardiopulmonary assessment in beta-thalassemia major. Chest 98 (1990) 1138-1142
17. Eldor A., Maclouf J., Lellouche F., Ben-Yashar V., Barenholz Y., Durst R., et al. A chronic hypercoagulable state and life-long platelet activation in beta thalassemia major. Southeast Asian J Trop Med Public Health 24 Suppl 1 (1993) 92-95
18. Eldor A., Lellouche F., Goldfarb A., Rachmilewitz E.A., and Maclouf J. In vivo platelet activation in beta-thalassemia major reflected by increased platelet thromboxane urinary metabolites. Blood 77 (1991) 1749-1753
19. Eldor A., Krausz Y., Atlan H., Snyder D., Goldfarb A., Hy-Am E., et al. Platelet survival in patients with beta-thalassemia. Am J Hematol 32 (1989) 94-99
20. Shebl S.S., el-Sharkawy H.M., and el Fadaly N.H. Haemostatic disorders in non-splenectomized and splenectomized thalassaemic children. East Mediterr Health J 5 (1999) 1171-1177
21. Atichartakarn V., Angchaisuksiri P., Aryurachai K., Chuncharunee S., and Thakkinstian A. In vivo platelet activation and hyperaggregation in hemoglobin E/β-thalassemia: a consequence of splenectomy. Int J Hematol 77 (2003) 299-303
22. Del Principe D., Menichjelli A.F., Giulio S., De Matteis W., Cianciculli P., and Papa G. PADGEM/GMP 140 expression on platelet membrane from homozygous beta-thalassemia patients. Br J Haematol 84 (1993) 111-117
23. Eldor A., Durst R., Hy-Am E., Goldfarb A., Gillis B., Rachmilewitz E.A., et al. A clronic hypercoagulable state in patients with beta-thalassaemia is already present in childhood. Br J Haematol 107 (1999) 739-746
24. O'Driscoll A., Mackie I.J., Porter J.B., and Machin S.J. Low plasma heparin cofactor II levels in thalassemia syndromes are corrected by chronic blood transfusion. Br J Haematol 90 (1995) 65-70
25. Cappellini M.D., Robbiolo L., Bottasso B.M., Coppola R., Fiorelli G., and Mannucci A.P. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 111 (2000) 467-473
26. Borenstein V., Barenholtz Y., Hy-Am E., Rachmilewitz E.A., and Eldor A. Phosphatidylserine in the outer leaflet of the red blood cells from beta thalassemia patients may explain the hypercoagulable state and thrombotic episodes. Am J Hematol 44 (1993) 33-35
27. Helley D., Eldor A., Girot R., Ducrooq R., Guillin M.C., and Bezeaud A. Comparision of the procoagulant activity of the red blood cells from patients with homozygous sickle cell disease and beta thalassemia. Thromb Haemost 76 (1996) 322-327
28. Hovav T., Goldfarb A., Artmann G., Yedgar S., and Barshtein G. Enhanced adherence of β-thalassemic erythrocytes to endothelial cells. Br J Haematol 106 (1999) 178-181
29. Pattanapanyasat K., Noulsri E., Fucharoen S., Lerdwana S., Lamchiagdhase P., Siritanaratkul N., et al. Flow cytometric quantitation of red blood cell vesicles in thalassemia. Cytometry B Clin Cytom 57 (2004) 23-31
30. Amer J., and Fibach E. Chronic oxidative stress reduces the respiratory burst response of neutrophils from beta-thalassaemia patients. Br J Haematol 129 (2005) 435-441
31. Rachmilewitz E.A., Weizer-Stern O., Adamsky K., Amariglio N., Breda L., et al. Role of iron in inducing oxidative stress in thalassemia: can it be prevented by inhibition of absorption and by antioxidants?. Ann N Y Acad Sci 1054 (2005) 118-123
32. Amer J., and Fibach E. Oxidative status of platelets in normal and thalassemic blood. Thromb Haemost 92 (2004) 1052-1059
33. Rosendaal F., Koster T., Vandenbrouck J., and Reitsma P. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85 (1995) 1504-1508
34. Zalloua P.A., Shbaklo H., Abou Mourad Y., Koussa S., and Taher A. Incidence of thromboembolic events in Lebanese thalassemia intermedia patients. Thromb Haemost 89 (2003) 767-768
35. Kahn J.E., Veyssier-Belot C., Renier J.L., de Mazancourt P., Peltier J.Y., and de Raucourt E. Recurrent thromboembolism in a patient with beta-thalassemia major associated with double heterozygosity for factor V R506Q and prothrombin G20210A mutations. Blood Coagul Fibrinolysis 13 (2002) 461-463
36. Borgna-Pignatti C., Carnelli V., Caruso V., De Mattia D., Di Palma A., et al. Thromboembolic events in beta thalassemia major: an Italian multicentric study. Acta Haematol 99 (1998) 76-79
37. Giordano P., Galli M., Del Vecchio G.C., Altomare M., Norbis F., Ruggeri L., et al. Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassemia. Br J Haematol 102 (1998) 903-906
38. Aessopos A., Farmakis D., Kanagiorga M., Rombos I., and Leucopolos D. Pseudoxanthoma elasticum lesions and cardiac complication as contributing factor for strokes in β-thalassemia patients. Stroke 28 (1997) 2421-2424
39. Michaeli J., Mittelman M., Grisaru D., and Rachmilewitz E.A. Thromboembolic complications in beta thalassemia major. Acta Haematol 87 (1992) 71-74
40. Wijburg F.A., vanden Burg W., van Tunenbroek A., and Weening R.S. Thrombo-embolic complications after splenectomy in HbE-beta-thalassaemia. Eur J Pediatr 147 (1988) 444-445
41. Wong V., Yu Y.L., Liang R.H.S., Tso W.K., Li A.M.C., and Chan T.K. Cerebral thrombosis in β-thalassaemia/hemoglobin E disease. Stroke 21 (1990) 812-816
42. Akar N., Kemahli S., Uysal Z., and Cin S. Thromboembolism in β-thalassemia major. Acta Haematol 100 (1998) 166
43. Senanayake M.P., and Lamabadusuriya S.P. Cerebral thrombosis in beta-thalassemia major. Indian J Pediatr 68 (2001) 1081-1082
44. Rosman N.P., Wu J.K., and Caplan L.R. Cerebellar infarction in the young. Stroke 23 (1992) 763-766
45. Baglin C., Brown K., Luddington R., and Baglin T. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group. Br J Haematol 100 (1998) 764-768
46. Arruda V.R., von Zuben P.M., Chiaparini L.C., Annichino-Bizzacchi J.M., and Costa F.F. The mutation Ala677 → Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 77 (1997) 818-821
47. Merli G., Spiro T.E., Olsson C.G., Abildgaard U., Davidson B.L., Eldor A., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 134 (2001) 191-202
48. Goldstein L.B., Adams R., Alberts M.J., Appel L.J., Brass L.M., Bushnell C.D., et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006) 1583-1633
49. Faxon D.P., and Nesto R.W. Antiplatelet therapy in populations at high risk of atherothrombosis. J Natl Med Assoc 98 (2006) 711-721